SABSW · Insider Trading
SAB Biotherapeutics, Inc. Warrant
Every open-market purchase and sale reported by SABSW officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-25 | Alexandra Kropotova | CHIEF MEDICAL OFFICER | F | −988 | — |
| 2026-02-05 | Christoph Lawrence Bausch | CHIEF OPERATING OFFICER | A | +1,800,000 deriv. | — |
| 2026-02-05 | Lucy To | See Remarks | A | +2,400,000 deriv. | — |
| 2026-02-05 | Eddie Joe Sullivan | PRESIDENT | A | +3,000,000 deriv. | — |
| 2026-02-05 | Alexandra Kropotova | CHIEF MEDICAL OFFICER | A | +2,400,000 deriv. | — |
| 2026-02-05 | Samuel J Reich | CEO | A | +4,800,000 deriv. | — |
| 2026-01-07 | David Zaccardelli | Director | A | +240,000 deriv. | — |
| 2026-01-07 | Rita Jain | Director | A | +240,000 deriv. | — |
| 2025-12-18 | Jay S Skyler | Director | A | +150,000 deriv. | — |
| 2025-12-18 | William James Polvino | Director | A | +150,000 deriv. | — |
| 2025-12-18 | Erick Lucera | Director | A | +150,000 deriv. | — |
| 2025-12-18 | Helen K. Ellias | Director | A | +150,000 deriv. | — |
| 2025-12-18 | Scott Giberson | Director | A | +150,000 deriv. | — |
| 2025-12-18 | David Link | Director | A | +150,000 deriv. | — |
| 2025-12-12 | Alexandra Kropotova | CHIEF MEDICAL OFFICER | F | −988 | — |
| 2025-10-01 | Sessa Capital (Master), L.P. | Director | M | +8,700,000 | +$15.22M |
| 2025-10-01 | Andrew Moin | Director | M | +1,740,000 | +$3.04M |
| 2025-09-22 | Alexandra Kropotova | CHIEF MEDICAL OFFICER | F | −1,977 | — |
| 2025-08-28 | Alexandra Kropotova | CHIEF MEDICAL OFFICER | A | +2,400,000 deriv. | — |
| 2025-08-28 | Lucy To | See Remarks | A | +1,200,000 deriv. | — |
| 2025-08-28 | Christoph Lawrence Bausch | CHIEF OPERATING OFFICER | A | +600,000 deriv. | — |
| 2025-08-28 | Eddie Joe Sullivan | PRESIDENT | A | +3,000,000 deriv. | — |
| 2025-08-28 | Samuel J Reich | CEO & EXECUTIVE CHAIRMAN | A | +4,800,000 deriv. | — |
| 2025-07-24 | Andrew Moin | Director | A | +571,250 deriv. | — |
| 2025-07-24 | Sessa Capital IM, L.P. | Director | A | +2,856,250 deriv. | — |
| 2025-04-01 | Alexandra Kropotova | CHIEF MEDICAL OFFICER | F | −1,179 | — |
| 2024-12-31 | Alexandra Kropotova | CHIEF MEDICAL OFFICER | F | −9,072 | — |
| 2024-11-05 | Helen K. Ellias | Director | A | +55,000 deriv. | — |
| 2024-08-13 | Lucy To | See Remarks | A | +125,000 deriv. | — |
| 2024-07-17 | Scott Giberson | Director | A | +20,000 deriv. | — |
| 2024-07-17 | Jeffrey G Spragens | Director | A | +20,000 deriv. | — |
| 2024-07-17 | Jay S Skyler | Director | A | +55,000 deriv. | — |
| 2024-07-17 | Erick Lucera | Director | A | +20,000 deriv. | — |
| 2024-07-17 | Eddie Joe Sullivan | PRESIDENT | A | +50,975 deriv. | — |
| 2024-07-17 | David Charles Link | Director | A | +29,305 deriv. | — |
| 2024-07-17 | William James Polvino | Director | A | +33,958 deriv. | — |
| 2024-07-17 | Christine E Hamilton | Director | A | +76,790 deriv. | — |
| 2024-07-17 | Samuel J Reich | CEO & EXECUTIVE CHAIRMAN | A | +35,700 deriv. | — |
| 2024-02-23 | Christoph Lawrence Bausch | CHIEF OPERATING OFFICER | A | +140,000 deriv. | — |
| 2024-02-23 | Alexandra Kropotova | CHIEF MEDICAL OFFICER | A | +140,000 deriv. | — |
| 2024-02-23 | Samuel J Reich | CEO & EXECUTIVE CHAIRMAN | A | +434,000 deriv. | — |
| 2024-02-23 | Eddie Joe Sullivan | PRESIDENT | A | +190,000 deriv. | — |
| 2024-02-23 | Michael King | CHIEF FINANCIAL OFFICER | A | +115,000 deriv. | — |
| 2023-12-08 | Eddie Joe Sullivan | Chief Executive Officer | Buy | +1,740 | +$1.53K |
| 2023-11-30 | Michael King | CHIEF FINANCIAL OFFICER | Buy | +5,000 | +$4.50K |
| 2023-11-30 | Samuel J Reich | Executive Chairman | Buy | +11,000 | +$9.84K |
| 2023-11-28 | Helen K. Ellias | Director | M | +2,857,142 | — |
| 2023-11-28 | Andrew Moin | Director | M | +4,584,571 | — |
| 2023-11-28 | John Petry | Director | M | +22,922,855 | — |
| 2023-11-15 | Andrew Moin | Director | A | +13,269 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Eddie Joe Sullivan | PRESIDENT | 5,232,304 | $5.76K |
| Helen K. Ellias | Director | 2,857,142 | $3.14K |
| Sessa Capital (Master), L.P. | Director | 2,198,457 | $2.42K |
| Andrew Moin | Director | 2,198,457 | $2.42K |
| Samuel J Reich | CEO | 766,699 | $843 |
| Alexandra Kropotova | CHIEF MEDICAL OFFICER | 43,296 | $48 |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the SABSW quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.